Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Topline results for non-steroidal immunomodulator for postop inflammation ➤ Pilot study describes use of prosthetic device for treatment of dry eye ➤ First patient dosed in Phase 3 trial investigating wet AMD treatment ➤ Acquisition and partnership news ➤ ASCRS news and events
➤ FDA clears device for MGD treatment ➤ Significant investments made in whole-eye transplant research ➤ Enrollment completed early in Phase 3 trial for novel glaucoma drop ➤ Studies make progress with gene and mRNA-based therapies for retinal conditions ➤ ASCRS news and events
➤ Topline Phase 3 results for sublingual, opioid-free sedation ➤ Phase 1 results for non-surgical cell therapy for corneal edema ➤ First Phase 2 study evaluates wet AMD gene therapy in both eyes of patients ➤ Update on Phase 3 study evaluating treatment for progressive myopia ➤ FDA to review NDA for first-in-class dry eye treatment ➤ Enrollment complete for Phase 1/2 study evaluating novel IOP-lowering drug delivery platform ➤ ASCRS news and events
➤ Investigational drug-eluting contact lens for glaucoma sees positive results ➤ First clinical-stage RNA-targeting therapy for nAMD ➤ PDUFA data extended for BLA for treatment of macular telangiectasia ➤ Three rare disease designations granted to investigational gene therapy treatments ➤ Partnership and acquisition news ➤ ASCRS news and events
➤ FDA authorizes first device treatment for dry AMD ➤ Fast track designation granted to retinopathy of prematurity prevention therapy ➤ Fluorescent hydrogel for cataract surgery ➤ ASCRS news and events
➤ Positive topline Phase 3 data for presbyopia drop ➤ Topline results for oral therapy targeting geographic atrophy ➤ Positive topline results from Phase 2 sustained-delivery drug for DME ➤ Study assesses new virtual reality simulator for phaco ➤ ASCRS news and events
➤ Positive topline Phase 3 confirmatory trial results for transepithelial crosslinking ➤ 18-month data from first-in-human drug-eluting IOL ➤ New Phase 2 findings for investigational geographic atrophy treatment ➤ Study: long-term, low-dose antiviral treatment reduces risk for HZO patients ➤ Acquisition news ➤ ASCRS news and events
➤ FDA approves new ‘full range of vision’ IOL ➤ Imaging platform designed for patients in supine position receives FDA clearance ➤ Last patient dosed in Phase 3 study of non-IV, non-opioid sedation method ➤ Phase 2 study begins to assess neuropathic corneal pain treatment ➤ Plans to submit BLA for treatment of severe vision loss due to retinitis pigmentosa ➤ Research discovers protein related to AMD ➤ ASCRS news and events
➤ Last patient visit in proof-of-concept cell therapy ➤ Phase 2 data for allergic eye inflammation drop published ➤ NDA resubmission to the FDA for topical ocular reproxalap ➤ Positive topline results from Phase 2b suprachoroidal wet AMD therapy ➤ Complimentary access to video journal ➤ Partnership news ➤ ASCRS news and events
➤ Roll-out expanded for presbyopia-correcting IOL ➤ Study: Phase 3 clinical trials evaluate phentolamine ophthalmic solution ➤ AI listening innovation for ophthalmologists ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.